Business Context and Reporting Period
This Form 8-K Current Report was filed by AngioDynamics, Inc. on November 5, 2013, covering events occurring on November 1, 2013. The filing details the Board of Directors' approval of a new Total Shareholder Return (TSR) Performance Unit Award Program under the company's 2004 Stock and Incentive Award Plan.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
On November 1, 2013, the Board approved performance unit awards for specific members of the Executive Management Team. The awards are contingent on the company's TSR relative to a pre-defined peer group over a three-year period (August 6, 2013, to May 31, 2016).
- Performance Cycles: Vesting is measured in two annual cycles and one aggregate three-year cycle.
- Vesting Range: The number of shares vesting ranges from 0% to 200% of the Target Amount based on TSR percentile ranking.
- Named Executive Officers and Target Amounts:
- Joseph M. DeVivo: 36,676 shares
- Mark T. Frost: 10,025 shares
- Stephen J. McGill: 7,176 shares
- Richard A. Stark: 7,126 shares
Guidance, Risks, and Contingencies
The filing outlines specific contingencies regarding employment termination:
- Death, Retirement, or Disability: Awards remain eligible to vest pro-rated based on months of service during the performance period.
- Other Termination: If employment is terminated for any other reason, the Performance Unit Award terminates immediately, and no shares are issued.
Full terms and conditions are detailed in Exhibits 10.1 and 10.2, which are incorporated by reference.
Investor Verification Checklist
- Verify the composition of the "Peer Group" used for TSR comparison in Exhibit 10.2.
- Review the specific vesting schedule and payment eligibility criteria in the Form of Performance Unit Award Agreement (Exhibit 10.1).
- Confirm the total potential equity dilution based on the 200% maximum vesting cap for all executive awards.
- Monitor future 8-K filings for actual vesting outcomes following the First and Second Performance Cycles.